Recruiting studies: Cancer Treatment Induced Thrombocytopenia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleuk
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06759636 Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)
Phase 1 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07110090 Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Le
Phase 2 · 1 location(s) · Anhui Provincial Hospital · NCT06898983 Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07441720 QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
Phase 2/Phase 3 · 2 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06456528 Herombopag Treated T-DM1 Induced Platelet Reduction
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT07257809

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.